ArticleJournal of surgical oncology2019
Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?
Article in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Impact of Sex and Deprivation on Neuroendocrine Tumour Survival: Challenges of Heterogeneous Data.Neuroendocrinology · 2025Pooled it
- [Duodenal neuroendocrine neoplasms (NEN): update on endoscopic and surgical management].Chirurgie (Heidelberg, Germany) · 2026Review
- Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).World journal of surgery · 2026Article
- Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.The Journal of surgical research · 2024Article
- Endoscopic Resection for Duodenal Neuroendocrine Neoplasms between 10 and 20 mm-A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Reply to: Striking a balance: Deciphering the dilemma of treatment equivalence in cardia gastric cancer.Journal of surgical oncology · 2023Article
- Development and Validation of Prognostic Nomograms for Periampullary Neuroendocrine Neoplasms: A SEER Database Analysis.Current oncology (Toronto, Ont.) · 2022Article
- Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are.World journal of gastroenterology · 2022Article
- Current Oncologic Standards for Surgery of Small Bowel Cancers.Journal of gastrointestinal cancer · 2022Article
- Management of Duodenal Neuroendocrine Tumors: Surgical versus Endoscopic Mucosal Resection.Annals of surgical oncology · 2022Article
- Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy.Journal of endocrinological investigation · 2021Article
- Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours-A Single Centre Cohort.Cancers · 2021Article
- Endoscopic Management of Diminutive Duodenal Neuroendocrine Tumors.Journal of gastrointestinal cancer · 2021Review
- Review
- Development and Validation of Prognostic Nomograms for Patients with Duodenal Neuroendocrine Neoplasms.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWhile sub-2 cm pancreatic neuroendocrine tumors (NETs) are often observed, small bowel-NETs undergo resection and lymphadenectomy regardless of size. Aim was to define the natural history of duodenal (D-NETs), determine the role of resection, and define the factors associated with overall survival (OS) after resection.
methodsNational Cancer Database (2004-2014) was queried for the patients with nonmetastatic/nonfunctional D-NETs. Local resection (LR): local excision/polypectomy/excisional biopsy. Anatomic resection (AR): radical surgery. Tumor size was divided into less than 1 cm, 1 to 2 cm, and ≥2 cm. Propensity score weighting was used to create balanced resection and no-resection cohorts. The primary endpoint was OS.
resultsAmong 5502 patient, the median age was 65 years. The median follow-up was 49 months. The median tumor size was 0.8 cm. Resection was performed in 72% (n = 3954; LR: 61%, AR: 39%). Lymph node (LN) resection was performed in 26% (43% had metastasis). A total of 74% had negative margins. Resection and no-resection cohorts were propensity score weighted for age/sex/race/Charlson-Deyo score/tumor grade (all independently associated with OS on multivariable analysis). Resection was associated with improved median OS compared to no resection in all sizes (<1 cm: median not reached vs 194 months; 1-2 cm: median not reached vs 56 months; >2 cm: median not reached vs 90 months; all P < .01). Subset analysis of each resection size cohort demonstrated that neither type of resection, LN retrieval, LN positivity, or margin status was associated with OS (all P > .05).
conclusionPatients with nonmetastatic and nonfunctional D-NETS should be considered for resection regardless of tumor size. Given the lack of prognostic value, the resection type and extent of LN retrieval should be tailored to each patient's clinical picture and safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.